SAG
VNDA icon

SageView Advisory Group’s Vanda Pharmaceuticals VNDA Stock Holding History

SageView Advisory Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-225
Closed -$1.99K – 2374
2025
Q4 		$1.99K Buy
+225
New +$1.24K ﹤0.01% 2234
2024
Q2 		– Sell
-8,249
Closed -$333K – 791
2024
Q1 		$333K Buy
+8,249
New +$33K 0.02% 392

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SageView Advisory Group's VNDA Position: Q1 2026 in Review

SageView Advisory Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 225 shares — an estimated $1.99K sold.

SageView Advisory Group first reported a position in VNDA in Q1 2024 and held it in 2 quarters. The position peaked at $333K in Q1 2024. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • SageView Advisory Group reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 225 Vanda Pharmaceuticals shares in Q1 2026, an estimated $1.99K.
  • SageView Advisory Group first reported a position in Vanda Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • SageView Advisory Group's Vanda Pharmaceuticals position peaked at $333K in Q1 2024.
  • 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.